| Market Cap | 225.61B | P/E | 29.21 | EPS this Y | - | Ern Qtrly Grth | 17.20% |
| Income | 9.11B | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 6.00% |
| Sales | 47.73B | PEG | - | EPS past 5Y | - | 200D Avg Chg | 16.00% |
| Dividend | 3.00% | Price/Book | 4.23 | EPS next 5Y | - | 52W High Chg | - |
| Recommedations | - | Quick Ratio | 0.61 | Shares Outstanding | 2.04B | 52W Low Chg | 45.00% |
| Insider Own | 4.12% | ROA | 8.65% | Shares Float | 1.96B | Beta | 0.48 |
| Inst Own | 39.34% | ROE | 19.83% | Shares Shorted/Prior | -/- | Price | 106.05 |
| Gross Margin | 74.61% | Profit Margin | 31.94% | Avg. Volume | 25,562 | Target Price | - |
| Oper. Margin | 30.78% | Earnings Date | - | Volume | 200 | Change | 0.00% |
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.